vTv Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- vTv Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- High Point
- Headquarters state / province
- North Carolina
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- VTVT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001641489
- EIN
- 47-3916571
Board of directors
-
Anne M. Phillips · DirectorSince 2024
-
Chandresh Harjivan · DirectorSince 2023
- Since 2024
-
Fahed Al-Marzooqi · DirectorSince 2023
- Since 2024
-
Hersh Kozlov · DirectorSince 2023
-
Howard L. Weiner · DirectorSince 2023
-
John A. Fry · DirectorSince 2023
-
Jonathan Isaacsohn · DirectorSince 2023
- Since 2024
-
Keith R. Harris · DirectorSince 2023
-
Paul J. Sekhri · Director · Pres, CEO and Exec ChairpersonSince 2024
-
Raymond Cheong · DirectorSince 2024
- Since 2024
Chief executives
Paul J. Sekhri
· Pres, CEO and Exec Chairperson
Dates unknown
Director election results
Annual meeting of June 26, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
90.1%
Board connections
10 of this board's directors also sit on 30 other boards.
- via Felix Baker, Julian Baker and Raymond Cheong
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Srinivas Akkaraju
- via Paul J. Sekhri
- via Hersh Kozlov
- via John A. Fry
- via Srinivas Akkaraju
- via Daniel K. Spiegelman
- via Daniel K. Spiegelman
- via Keith R. Harris
- via Srinivas Akkaraju
- via Daniel K. Spiegelman
- via Anne M. Phillips
- via Srinivas Akkaraju
- via Daniel K. Spiegelman
- via Hersh Kozlov
- via Paul J. Sekhri
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 22, 2025 | Srinivas Akkaraju Director | Grant or award | +106,000 | $15.27 | $1,618,620 |
| Sep 3, 2025 | Julian Baker Director | Grant or award | +4,308 | — | — |
| Sep 3, 2025 | Julian Baker Director | Grant or award | +46,692 | — | — |
| Nov 18, 2024 | Paul J. Sekhri Director, Officer (Pres, CEO and Exec Chairperson) | Open-market purchase | +1,844 | $16.96 | $31,274 |
| Nov 15, 2024 | Paul J. Sekhri Director, Officer (Pres, CEO and Exec Chairperson) | Open-market purchase | +1,378 | $16.35 | $22,530 |
| Nov 15, 2024 | Paul J. Sekhri Director, Officer (Pres, CEO and Exec Chairperson) | Open-market purchase | +1,778 | $16.88 | $30,013 |
| Mar 5, 2024 | 667, L.P. Director | Sold back to the company | −4,776 | — | — |
| Mar 5, 2024 | Samsara BioCapital, L.P. 10% owner | Other | −58,836 | — | — |
| Mar 5, 2024 | Srinivas Akkaraju Director, 10% owner | Sold back to the company | −58,836 | — | — |
| Mar 5, 2024 | 667, L.P. Director | Sold back to the company | −52,881 | — | — |
| Feb 27, 2024 | Srinivas Akkaraju Director, 10% owner | Grant or award | +224,732 | $11.81 | $2,654,085 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.